

1 Manuscript

1 **Epidemiological profile of patients diagnosed with covid-19 in the municipality**
2 **of São Gonçalo, Rio de Janeiro, Brazil**

3

4 Raphael Rangel das Chagas, M.Sc.¹, Hércules Rezende Freitas, Ph.D.², Sergian Vianna
5 Cardozo, Ph.D.¹

6

7 ¹Interinstitutional Graduate Program in Translational Biomedicine (BIOTRANS), School of Health
8 Sciences, Grande Rio University, Duque de Caxias, RJ, Brazil; ²Laboratory of Inborn Errors of
9 Metabolism, Leopoldo de Meis Institute of Medical Biochemistry, Federal University of Rio de Janeiro,
10 Rio de Janeiro, RJ, Brazil.

11

12

13

14 ORCIDS:

15

16 Raphael Rangel das Chagas: 0000-0002-9503-9439

17 Hércules Rezende Freitas: 0000-0003-1584-9157

18 Sergian Vianna Cardozo: 0000-0003-2990-7936

19

20 Authors' e-mail addresses:

21

22 Raphael Rangel das Chagas: raphael.chagas@unigranrio.edu.br

23 Hércules Rezende Freitas: hercules.freitas@bioqmed.ufrj.br

24 Sergian Vianna Cardozo: sergian.cardozo@unigranrio.edu.br

25

26 *Corresponding author: Raphael Rangel das Chagas

27

28 Interinstitutional Graduate Program in Translational Biomedicine (BIOTRANS),
29 School of Health Sciences, Grande Rio University, Duque de Caxias, RJ, Brazil. E-mail
30 address: raphael.chagas@unigranrio.edu.br. Phone number: +55 21 99274-1235.

31

32

33

2 Manuscript

34 **Abstract**

35

36 Objectives: The global health crisis caused by SARS-CoV-2 has led to over 760 million
37 confirmed cases and 6.8 million deaths worldwide, primarily impacting the
38 respiratory system with symptoms varying from mild to severe. This study aimed to
39 analyze the interplay between vaccination status, sociodemographic profiles,
40 comorbidities, and COVID-19 outcomes.

41 Study Design: Observational, cross-sectional, and analytical.

42 Methods: The study analyzed data from 6,953 individuals, examining vaccination
43 statuses, sociodemographic profiles, comorbidities, COVID-19 test results, and other
44 relevant variables. The cohort comprised predominantly mixed-race (51%),
45 Caucasian (38%), and Black (9.5%) individuals, with 61% being female and 60% aged
46 between 21-50 years. Prevalent comorbidities included hypertension (18.2%),
47 diabetes (4.9%), and obesity (0.4%).

48 Results: Population-weighted analysis revealed significant associations between
49 sociodemographic factors and COVID-19 test outcomes. Younger age groups,
50 particularly 11-30 years, had higher positivity rates, which declined with age.
51 Caucasians exhibited higher positivity rates (40.1%) compared to other ethnicities.
52 Cramér's V indicated small correlations between symptoms and test outcomes,
53 notably with loss of taste ($V = 0.11$) and smell ($V = 0.08$). Odds ratio analysis identified

3 Manuscript

53 hypertension as significantly associated with higher COVID-19 positivity (OR = 1.54,
54 95% CI: 1.28-1.83, $p < 0.001$), while obesity was associated with lower positivity (OR =
55 0.13, 95% CI: 0.02-0.63, $p = 0.025$). Symptoms such as fever, cough, loss of taste, loss
56 of smell, and myalgia also showed significant associations with positive test
57 outcomes.

58 Conclusions: This study provides valuable insights into the complex interplay of
59 sociodemographic characteristics, comorbidities, symptoms, and COVID-19
60 outcomes.

61

62 **Keywords:** SARS-CoV-2; COVID-19; Pandemic; Vaccination; Immunity; Public Health

63

64 Introduction

65

66 SARS-CoV-2, a virus from the *Coronaviridae* family, *Betacoronavirus* genus, and
67 *Sarbecovirus* subgenus, causes severe acute respiratory syndrome coronavirus 2
68 (SARS-CoV-2). This enveloped, roughly spherical virus measures 60-140 nm in
69 diameter and has a single strand of positive-sense RNA, about 30,000 nucleotides
70 long ¹. SARS-CoV-2 is highly contagious, spreading through respiratory droplets and
71 contact with contaminated surfaces ².

4 Manuscript

72 The high transmissibility of SARS-CoV-2 led to an outbreak in Wuhan, China, in
73 late 2019, sparking the global COVID-19 pandemic ³. The pandemic has become a
74 significant public health challenge worldwide, resulting in over 760 million
75 confirmed cases and 6.8 million deaths ⁴. The virus primarily affects the respiratory
76 system, with symptoms ranging from mild to severe, including fever, cough,
77 shortness of breath, fatigue, pneumonia, multiple organ failure, and death ⁵.

78 To combat the pandemic, various measures, including the development of
79 vaccines, have been implemented. Vaccination is a primary strategy to prevent
80 infection and reduce disease severity ^{6,7}. The rapid development of COVID-19
81 vaccines has involved global efforts, with numerous candidate vaccines in progress
82 ⁸⁻¹⁰.

83 The pandemic has disrupted national vaccination schedules, particularly for
84 children under 12 months, causing delays in their vaccinations ¹¹. The continuous
85 development of COVID-19 vaccines is crucial in controlling the virus spread and
86 reducing cases.

87 In this study, we analyzed data from 6,953 individuals who received COVID-
88 related care in São Gonçalo, Rio de Janeiro, Brazil. Our goal was to examine
89 sociodemographic characteristics such as age, ethnicity, and gender in relation to
90 COVID-19 testing results. We also aimed to identify common comorbidities,
91 especially hypertension, among those who tested positive, and to investigate the

5 Manuscript

92 prevalence of key symptoms, including fever above 38.5°C, loss of smell, and loss of
93 taste, among participants who tested positive and negative.

94

95 **Methods**

96

97 *Experimental design*

98

99 The experimental design of this study is observational, cross-sectional, and
100 analytical. The study population consists of patients who sought care at screening
101 centers in São Gonçalo, a municipality in the state of Rio de Janeiro, Brazil, between
102 July 28, 2021, and December 2, 2021.

103 According to the Brazilian Institute of Geography and Statistics (IBGE), São
104 Gonçalo spans a territorial area of 248.160 km². In 2022, the resident population was
105 estimated at 896,744 people, resulting in a population density of 3,613.57
106 inhabitants per km². The school enrollment rate for children aged 6 to 14 was 96.7%
107 in 2010, and the Municipal Human Development Index (MHDI) was 0.739.
108 Economically, the Gross Domestic Product (GDP) per capita was R\$ 18,504.81 in
109 2021. Infant mortality, a critical health indicator, was 12.33 deaths per thousand live
110 births in 2020 ¹².

111

6 Manuscript

112 *Inclusion criteria and informed consent*

113

114 Patients included in the study exhibited clinical symptoms suggestive of SARS-
115 CoV-2 infection and underwent COVID-19 testing using the RT-LAMP technique. The
116 screening centers in São Gonçalo served as locations for data collection and sample
117 analysis.

118 This study adhered to the ethical principles outlined in the Declaration of
119 Helsinki and relevant Brazilian legislation. Rigorous measures were implemented to
120 ensure patient confidentiality, with all data anonymized before analysis. The
121 research protocol was reviewed and approved by the Research Ethics Committee of
122 the University of Grande Rio (CEP/UNIGRANRIO) under CAAE number
123 32362220.1.0000.5283.

124 All participants were thoroughly informed about the study's objectives and
125 potential risks and provided written informed consent to participate. Participation
126 was voluntary, with no coercion or pressure applied, and participants retained the
127 right to withdraw their consent at any time without facing any adverse
128 consequences. The study was conducted following the highest ethical standards,
129 ensuring the integrity and dignity of both participants and researchers.

130

131 *Data collection*

7 Manuscript

132

133 Data collection at screening centers in São Gonçalo, Rio de Janeiro, included
134 sociodemographic characteristics, comorbidities, COVID-19 symptoms, vaccination
135 history, and COVID-19 test results. Patient age was determined by recording the
136 date of birth and the date of sample collection. Ethnicity was documented to
137 understand ethnic diversity. Comorbidities such as hypertension, diabetes, and
138 obesity were detailed, along with other comorbidities.

139 The onset date of COVID-19 symptoms and specific symptoms reported,
140 including runny nose, fever, loss of smell and taste, diarrhea, headache, shortness of
141 breath, muscle pain, and cough, were recorded. COVID-19 test results, using the RT-
142 LAMP technique, were documented as positive or negative. The number of COVID-19
143 vaccine doses received, the type of vaccine administered, and the date of
144 administration were also recorded.

145 Healthcare professionals, adhering to safety and ethical protocols, conducted
146 data collection. Participants were informed about the data collection purpose and
147 provided written informed consent. Data confidentiality was maintained, and
148 information was handled anonymously.

149

150 *Statistical analysis*

151

8 Manuscript

152 The statistical analysis for this study was conducted using RStudio (version
153 2023.06.1 + 524) with the R programming language (version 4.2.2).

154 Through univariate analysis, we aimed to describe the profile of the
155 participants, identify the number of non-responses, and detect outliers. Data
156 presented in Tables 1 to 6 include the analysis of sociodemographic characteristics,
157 comorbidities, COVID-19 test results, and other relevant variables. This analysis was
158 conducted using absolute and relative frequencies as well as mean values.

159 Bivariate analysis was performed to examine significant associations between
160 study variables. Considering that the data was collected from a convenience
161 sample, weights were calculated by post-stratification based on the known
162 populational (IBGE, 2024) ethnicity and sex distributions. Then, the Pearson's chi-
163 square test (χ^2) with Rao & Scott adjustment was employed to evaluate the
164 associations between study variables:

165

$$\chi^2_{\omega} = \frac{\left(\sum \frac{(O_{ij} - E_{ij})^2}{E_{ij}} \right)}{D_{ef}}$$

167

168 Where χ^2_{ω} represents the (weighted) adjusted chi-square test statistic, O_{ij}
169 denotes the observed frequency counts, E_{ij} denotes the expected frequency counts,
170 and D_{ef} is the calculated design effect. This methodological approach is consistent

9 Manuscript

171 with the literature on statistical data analysis in health, as highlighted by ¹³, who
172 emphasize the importance of univariate and bivariate analyses and the application
173 of the Pearson chi-square test for categorical variable associations.

174 Additionally, to assess the strength of associations identified by the χ^2 test, a
175 weighted Cramer's V was calculated:

176

$$177 \quad V_{\omega} = \sqrt{\frac{\chi^2_{\omega}}{N_{\omega} \times \min(r-1, c-1)}}$$

178

179 Where V_{ω} indicates the strength of association between variables (Cramer's
180 V), χ^2_{ω} is the weighted χ^2 test statistic, N_{ω} is the total weight (sum of all weights), r is the
181 number of rows in the contingency table, and c is the number of columns in the
182 contingency table. For interpretive purposes, χ^2_{ω} and V_{ω} values with p less than 0.05
183 were considered statistically significant, allowing for the rejection of the null
184 hypothesis.

185 Finally, to analyze the relationship between various study variables, odds
186 ratios (OR) were calculated, providing a measure of association between exposure
187 variables and the outcome variable, which in this case is the result of the COVID-19
188 test. The OR was calculated as:

189

10 Manuscript

190
$$L(\beta) = \sum_{i=1}^n \omega_i [y_i \log(p_i) + (1 - y_i) \log(1 - p_i)]$$

191

192
$$OR = e^{\beta_j}$$

193

194 Where $L(\beta)$ is the log-likelihood function, p_i is the predicted probability that $Y_i =$
195 1, OR is the weighted odds ratio for a given predictor, and β_j is the estimated
196 coefficient for the predictor. For each calculated OR , a 95% confidence interval (CI)
197 was also computed to assess the precision of the estimate. Also, for interpretative
198 purposes, a p-value less than 0.05 considered statistically significant. This approach
199 ensures that the identified associations are less likely to derive from random chance.

200

201 **Results**

202

203 Table 1 details the sociodemographic characteristics of the study participants,
204 categorizing them by age group, ethnicity, and gender. Age groups ranged from 10
205 to 81 years and above. Ethnicity was classified into mixed-race (parda), Caucasian,
206 Black, other, and unknown. The data indicate that most participants were mixed-race
207 (51%), followed by Caucasian (38%) and Black (9.5%). Furthermore, a significant
208 proportion of the participants were female (61%). Age-wise, the largest group was

11 Manuscript

209 aged 21 to 50 years, comprising approximately 60% of the participants. Those aged
210 61 to 80 years constituted around 14%, while participants aged 81 years or older
211 made up about 1% of the total sample.

212 Key comorbidities (*i.e.*, obesity, hypertension, and type II diabetes) were also
213 examined (Supplementary table 1). Most participants did not report having diabetes
214 (95.1%), obesity (99.6%), or hypertension (81.8%). Among the comorbidities
215 reported, hypertension was the most prevalent (18.2%), followed by diabetes (4.9%)
216 and obesity (0.4%). This highlights hypertension as the most common comorbidity
217 within the study population.

218

219 **Table 1.** Sociodemographic characteristics of the cohort of participants (patients)
220 who were attended at the screening centers of São Gonçalo (RJ), during the period
221 from 07/28/2021 to 12/02/2021.

Variables	N = 6,953 ¹
AGE	
≤ 10 y.o.	10 (0.1%)
11 to 20 y.o.	491 (7.1%)
21 a 30 y.o.	1,419 (20%)
31 a 40 y.o.	1,406 (20%)
41 a 50 y.o.	1,457 (21%)
51 a 60 y.o.	1,142 (16%)
61 a 70 y.o.	679 (9.8%)
71 a 80 y.o.	274 (3.9%)
≥ 81 y.o.	75 (1.1%)
ETHNICITY	
Brown	3,490 (51%)
Caucasian	2,625 (38%)
Black	652 (9.5%)
Other	88 (1.3%)
Not available	98
SEX	
Female	4,263 (61%)
Male	2,690 (39%)

12 Manuscript

Variables	N = 6,953 ¹
-----------	------------------------

222

223 Table 2 presents additional variables beyond the comorbidities and
224 sociodemographic characteristics of the study participants. It details the number of
225 participants who experienced symptoms such as fever, runny nose, loss of smell, loss
226 of taste, diarrhea, headache, shortness of breath, and muscle pain. The table also
227 provides information on the participants' vaccination status, including the number
228 of doses received and the type of vaccine administered.

229 The data indicate that most participants did not have a fever above 38.5°C
230 (73.4%), runny nose (65.6%), loss of smell (86%), or loss of taste (85.9%). Moreover,
231 the majority received two vaccine doses (62.5%), with the Oxford-AstraZeneca
232 vaccine being the most administered (45%). Among the variables examined,
233 headache was the most frequently reported symptom, affecting 49% of the
234 participants.

235

236 **Table 2.** Symptoms, immunization, and geographical distribution in the sample of
237 participants (patients) who were attended at the screening centers of São Gonçalo
238 (RJ), during the period from 07/28/2021 to 12/02/2021.

Variables	N = 6,953 ¹
FEVER < 38.5 °C	
No	5,057 (73%)
Yes	1,828 (27%)
Not available	68
FEVER ≥ 38.5 °C	
No	5,893 (86%)
Yes	989 (14%)

13 Manuscript

Variables	N = 6,953 ¹
Not available	71
RHINITIS	
No	4,496 (65%)
Yes	2,382 (35%)
Not available	75
LOSS OF SMELL	
No	5,908 (86%)
Yes	956 (14%)
Not available	89
LOSS OF TASTE	
No	5,912 (86%)
Yes	968 (14%)
Not available	73
DIARRHEA	
No	6,354 (92%)
Yes	544 (7.9%)
Not available	55
HEADACHE	
No	3,483 (51%)
Yes	3,414 (49%)
Not available	56
DYSPNEA	
No	6,052 (88%)
Yes	824 (12%)
Not available	77
MYALGIA	
No	4,556 (66%)
Yes	2,316 (34%)
Not available	81
COUGH	
No	3,268 (48%)
Yes	3,580 (52%)
Not available	105
RESULT	
Negative	4,925 (72%)
Positive	1,953 (28%)
Not available	75
DOSE	
Unvaccinated	53 (1.0%)
First dose	1,578 (30%)
Second dose	3,298 (62%)
Third dose	206 (3.9%)
Single dose	142 (2.7%)
Not available	1,676
VACCINE	
Oxford - AstraZeneca	2,352 (45%)
Coronavac - Sinovac	1,163 (22%)
Pfizer - BNT162b2	1,532 (29%)
Janssen-Cilag	149 (2.9%)

14 Manuscript

Variables	N = 6,953 ¹
Not available	1,757
MUNICIPALITY	
São Gonçalo	6,851 (99%)
Other	102 (1.5%)
VACCINATED	
No	53 (1.0%)
Yes	5,224 (99%)
Not available	1,676

¹n (%)

239

240 Table 3 shows the relationship between the sociodemographic profile of
241 participants and their COVID-19 test results, detailing age, ethnicity, and gender.
242 Younger individuals, specifically those aged 11-20 years, showed a higher positivity
243 rate (7.4%) compared to the negative group (6.8%). This trend continued with the 21-
244 30 years (18.0% positive) and 31-40 years (17.8% positive) groups, though these
245 groups also had substantial negative test rates (21.3% and 21.1%, respectively).
246 Positivity rates decreased with age, with a notable difference in the 71-80 years
247 group (6.8% positive vs. 2.8% negative). The 81+ years group had 1.3% positive and
248 1.0% negative.

249 Ethnicity showed significant variations. The brown ethnic group had nearly
250 half (49.9%) test positive, slightly lower than the negative group (51.2%). Caucasians
251 had a higher positivity rate (40.1%) compared to their negative counterparts (37.7%).
252 The black ethnic group had a slightly lower positivity rate (8.8%) compared to the
253 negative group (9.8%). Other ethnicities had almost identical positive (1.2%) and

15 Manuscript

254 negative (1.3%) rates. A small portion lacked ethnic classification, which did not
 255 significantly impact overall trends.

256 Gender analysis revealed no significant differences. Females constituted
 257 57.9% of positive cases and 62.9% of negative cases. Males represented 42.1% of
 258 positive cases and 37.1% of negative cases.

259

260 **Table 3.** Relationship between the sociodemographic profile and the COVID-19 test
 261 results of participants (patients) who were attended at the screening centers of São
 262 Gonçalo (RJ), during the period from 07/28/2021 to 12/02/2021.

Variables	COVID-19 TEST RESULT			p-value ²
	TOTAL, N = 6,878 ¹	NEGATIVE, N = 4,925 ¹	POSITIVE, N = 1,953 ¹	
AGE				0.000*
≤ 10 y.o.	10 (0.1%)	6 (0.1%)	4 (0.2%)	
11 to 20 y.o.	482 (7.0%)	337 (6.8%)	145 (7.4%)	
21 a 30 y.o.	1,399 (20.3%)	1,048 (21.3%)	351 (18.0%)	
31 a 40 y.o.	1,386 (20.2%)	1,039 (21.1%)	347 (17.8%)	
41 a 50 y.o.	1,441 (21.0%)	1,063 (21.6%)	378 (19.4%)	
51 a 60 y.o.	1,137 (16.5%)	796 (16.2%)	341 (17.5%)	
61 a 70 y.o.	676 (9.8%)	448 (9.1%)	228 (11.7%)	
71 a 80 y.o.	272 (4.0%)	139 (2.8%)	133 (6.8%)	
≥ 81 y.o.	75 (1.1%)	49 (1.0%)	26 (1.3%)	
ETHNICITY				0.002*
Brown	3,446 (50.8%)	2,490 (51.2%)	956 (49.9%)	
Caucasian	2,605 (38.4%)	1,836 (37.7%)	769 (40.1%)	
Black	646 (9.5%)	478 (9.8%)	168 (8.8%)	
Other	84 (1.2%)	61 (1.3%)	23 (1.2%)	
Not available	97	60	37	
SEX				0.394
Female	4,226 (61.4%)	3,096 (62.9%)	1,130 (57.9%)	
Male	2,652 (38.6%)	1,829 (37.1%)	823 (42.1%)	

¹n (%)

²Pearson χ^2 test

263

16 Manuscript

264 Table 4 illustrates the relationship between comorbidities and COVID-19 test
265 results. It details the number of participants who reported having hypertension,
266 diabetes, and obesity, as well as the number of participants who tested positive or
267 negative for COVID-19 within each comorbidity group.

268 The analysis of comorbidities and their association with COVID-19 test results
269 provides several key insights. Hypertension did not show a significant link to COVID-
270 19 test outcomes. Among those without hypertension, the positive test rate was
271 81.9%, nearly identical to the negative test rate of 81.8%. Similarly, 18.1% of
272 individuals with hypertension tested positive, compared to 18.2% who tested
273 negative.

274 Diabetes also did not exhibit a significant correlation with COVID-19 test
275 results. The data showed that 95.1% of individuals without diabetes tested positive,
276 while 95.0% tested negative. Among those with diabetes, 4.9% tested positive
277 compared to 5.0% negative. In contrast, obesity showed a significant association
278 with COVID-19 test results. The overwhelming majority of individuals without
279 obesity tested positive (99.7%) and negative (99.5%). However, among those with
280 obesity, only 0.3% tested positive compared to 0.5% negative.

281

282 **Table 4.** Comorbidities and COVID-19 test results.

17 Manuscript

Variables	COVID-19 TEST RESULT			p-value ²
	TOTAL, N = 6,878 ¹	NEGATIVE, N = 4,925 ¹	POSITIVE, N = 1,953 ¹	
HYPERTENSION				0.578
No	5,623 (81.8%)	4,026 (81.8%)	1,597 (81.9%)	
Yes	1,250 (18.2%)	896 (18.2%)	354 (18.1%)	
Not available	5	3	2	
DIABETES				0.230
No	6,529 (95.1%)	4,674 (95.0%)	1,855 (95.1%)	
Yes	339 (4.9%)	244 (5.0%)	95 (4.9%)	
Not available	10	7	3	
OBESITY				0.000*
No	6,825 (99.6%)	4,884 (99.5%)	1,941 (99.7%)	
Yes	29 (0.4%)	23 (0.5%)	6 (0.3%)	
Not available	24	18	6	

¹n (%)

²Pearson χ^2 test

283

284 Table 5 shows the relationship between symptoms, vaccination status, and
 285 COVID-19 test results. It categorizes participants based on the presence of fever
 286 >38.5°C, runny nose, loss of smell, loss of taste, diarrhea, headache, shortness of
 287 breath, muscle pain, and cough, as well as their vaccination status, and compares
 288 the number of positive and negative test results.

289 A significant proportion of positive cases had fever >38.5°C (15.8%), fever
 290 ≤38.5°C (34.9%), loss of smell (29.3%), and loss of taste (26.6%). Most negative cases
 291 did not have these symptoms. Dyspnea was more common in negative cases (13.1%
 292 vs. 9.1%), while myalgia was more frequent in positive cases (37.4% vs. 32.3%).

293 Regarding vaccination, 36.8% of first-dose recipients tested positive, while
 294 27.4% tested negative. For second-dose recipients, 54.4% tested positive, and 65.4%
 295 tested negative. Third-dose recipients had a positive test rate of 4.5%, slightly higher

18 Manuscript

296 than the negative rate of 3.7%. Single-dose recipients had an identical positive and
297 negative rate of 2.7%.

298 The type of vaccine did not show a significant association with test results.
299 Among Oxford-AstraZeneca recipients, 43.7% tested positive, and 46.0% tested
300 negative. CoronaVac-Sinovac had a positive rate of 27.1% and a negative rate of
301 20.7%. Pfizer-BNT162b2 had a positive rate of 26.3% and a negative rate of 30.4%.
302 Janssen-Cilag had a positive rate of 2.9% and a negative rate of 2.8%. This suggests
303 comparable effectiveness across different vaccines.

304 Overall vaccination status significantly related to test results. Among the
305 unvaccinated, 1.6% tested positive, while 0.8% tested negative.

306

307 **Table 5.** Other variables and the COVID-19 test results of participants (patients) who
308 were attended at the screening centers of São Gonçalo (RJ), during the period from
309 07/28/2021 to 12/02/2021.

Variables	COVID-19 TEST RESULT			p-value ²
	TOTAL, N = 6,878 ¹	NEGATIVE, N = 4,925 ¹	POSITIVE, N = 1,953 ¹	
FEVER < 38.5 °C				0.002*
No	5,034 (73.4%)	3,766 (76.7%)	1,268 (65.1%)	
Yes	1,824 (26.6%)	1,143 (23.3%)	681 (34.9%)	
Not available	20	16	4	
FEVER ≥ 38.5 °C				0.002*
No	5,873 (85.7%)	4,229 (86.3%)	1,644 (84.2%)	
Yes	982 (14.3%)	674 (13.7%)	308 (15.8%)	
Not available	23	22	1	
RHINITIS				0.059
No	4,490 (65.6%)	3,081 (62.8%)	1,409 (72.5%)	
Yes	2,359 (34.4%)	1,824 (37.2%)	535 (27.5%)	
Not available	29	20	9	
LOSS OF SMELL				0.000*

19 Manuscript

Variables	COVID-19 TEST RESULT			p-value ²
	TOTAL, N = 6,878 ¹	NEGATIVE, N = 4,925 ¹	POSITIVE, N = 1,953 ¹	
No	5,880 (86.0%)	4,506 (92.1%)	1,374 (70.7%)	
Yes	955 (14.0%)	385 (7.9%)	570 (29.3%)	
Not available	43	34	9	
LOSS OF TASTE				0.000*
No	5,886 (85.9%)	4,460 (90.9%)	1,426 (73.4%)	
Yes	965 (14.1%)	447 (9.1%)	518 (26.6%)	
Not available	27	18	9	
DIARRHEA				0.097
No	6,326 (92.1%)	4,522 (91.9%)	1,804 (92.5%)	
Yes	543 (7.9%)	397 (8.1%)	146 (7.5%)	
Not available	9	6	3	
HEADACHE				0.198
No	3,464 (50.4%)	2,414 (49.1%)	1,050 (53.8%)	
Yes	3,404 (49.6%)	2,504 (50.9%)	900 (46.2%)	
Not available	10	7	3	
DYSPNEA				0.005*
No	6,027 (88.0%)	4,259 (86.9%)	1,768 (90.9%)	
Yes	820 (12.0%)	642 (13.1%)	178 (9.1%)	
Not available	31	24	7	
MYALGIA				0.040*
No	4,532 (66.2%)	3,312 (67.7%)	1,220 (62.6%)	
Yes	2,311 (33.8%)	1,581 (32.3%)	730 (37.4%)	
Not available	35	32	3	
COUGH				0.818
No	3,265 (47.9%)	2,358 (48.2%)	907 (47.0%)	
Yes	3,555 (52.1%)	2,531 (51.8%)	1,024 (53.0%)	
Not available	58	36	22	
DOSE				0.002*
Unvaccinated	53 (1.0%)	31 (0.8%)	22 (1.6%)	
First dose	1,569 (29.9%)	1,057 (27.4%)	512 (36.8%)	
Second dose	3,280 (62.5%)	2,524 (65.4%)	756 (54.4%)	
Third dose	206 (3.9%)	144 (3.7%)	62 (4.5%)	
Single dose	141 (2.7%)	103 (2.7%)	38 (2.7%)	
Not available	1,629	1,066	563	
VACCINE				0.572
Oxford - AstraZeneca	2,347 (45.4%)	1,750 (46.0%)	597 (43.7%)	
Coronavac - Sinovac	1,158 (22.4%)	788 (20.7%)	370 (27.1%)	
Pfizer - BNT162b2	1,515 (29.3%)	1,156 (30.4%)	359 (26.3%)	
Janssen-Cilag	148 (2.9%)	108 (2.8%)	40 (2.9%)	
Not available	1,710	1,123	587	
VACCINATED				0.014*
No	53 (1.0%)	31 (0.8%)	22 (1.6%)	
Yes	5,196 (99.0%)	3,828 (99.2%)	1,368 (98.4%)	

20 Manuscript

Variables	COVID-19 TEST RESULT			p-value ²
	TOTAL, N =	NEGATIVE, N =	POSITIVE, N =	
Not available	6,878 ¹	4,925 ¹	1,953 ¹	
	1,629	1,066	563	

¹n (%)

²Pearson χ^2 test

310

311 In addition to analyzing the independence of the study variables, the strength
312 of the associations between the variables of interest and parameters such as
313 ethnicity, vaccination status, and the number of vaccine doses received was
314 evaluated using the same sample.

315 As depicted in Figure 1, loss of taste and smell show the greater (although
316 weak) correlations with the test results (Cramér's V = 0.08 and 0.11, respectively).
317 Low and high fever (highly intercorrelated, V = 0.25), as well as dyspnea, showed
318 equally negligible (although significant) correlations with test results (Cramér's V =
319 0.04). Finally, myalgia was the symptom with the smaller significant correlation with
320 test results (Cramér's V = 0.03).

321

322 **Figure 1.** Heatmap of the magnitude of association (weighted Cramer's V) between
323 the study variables and vaccination parameters, ethnicity, and vaccine dose.

21 Manuscript



324
 325 Cramer's V value with calculated probability less than *5% ($p < 0.05$), **1% ($p < 0.01$), and ***0.1% ($p <$
 326 0.001).

327
 328 Here, we also calculated odds ratios for various study variables against
 329 COVID-19 test results, shown in Figure 2. Hypertension was significantly associated
 330 with higher likelihood of testing positive (OR = 1.54, 95% CI: 1.28-1.83; $p = 2.67^{-6}$).
 331 Diabetes showed a trend towards higher likelihood but was not significant (OR =

22 Manuscript


332 1.30, 95% CI: 0.97-1.73; $p = 0.078$). Obesity was associated with a significantly lower
333 likelihood (OR = 0.13, 95% CI: 0.02-0.63; $p = 0.025$). Fever $>38.5^{\circ}\text{C}$ had a strong
334 association (OR = 2.55, 95% CI: 2.17-3.00; $p = 9.26^{-30}$), and fever $\leq 38.5^{\circ}\text{C}$ also showed
335 significant association (OR = 2.11, 95% CI: 1.80-2.48; $p = 6.68^{-20}$). Rhinitis was linked to
336 lower likelihood (OR = 0.68, 95% CI: 0.59-0.78; $p = 3.94^{-8}$). Loss of smell (OR = 3.65,
337 95% CI: 2.91-4.59; $p = 8.48^{-29}$) and loss of taste (OR = 2.05, 95% CI: 1.62-2.57; $p = 1.14$
338 $^{-9}$) were strong indicators of positive tests.

339 Diarrhea showed a non-significant trend towards lower likelihood (OR = 0.82,
340 95% CI: 0.65-1.04; $p = 0.107$). Headache showed no significant association (OR = 1.05,
341 95% CI: 0.92-1.20; $p = 0.483$). Dyspnea was strongly associated with lower likelihood
342 (OR = 0.33, 95% CI: 0.26-0.43; $p = 7.21^{-18}$). Myalgia (OR = 1.31, 95% CI: 1.15-1.50; $p =$
343 7.38^{-5}) and cough (OR = 1.42, 95% CI: 1.25-1.62; $p = 1.43^{-7}$) were significantly
344 associated with higher likelihood. Being male was also associated with higher
345 likelihood (OR = 1.23, 95% CI: 1.08-1.40; $p = 0.002$).

346

347 **Figure 2.** Weighted odds ratios evaluating study variables against covid-19 test
348 results.

23 Manuscript



349

350

351 Discussion

352

353 Sociodemographic Variables

354

24 Manuscript

355 Age, race, ethnicity, and gender significantly impact COVID-19 infection and
356 outcomes. According to Table 4, 74.5% of individuals who tested positive for COVID-
357 19 were over 31 years old, with the highest prevalence among those aged 41 to 50
358 years (19.4%). Age significantly influences COVID-19 status and progression, with
359 individuals over 65 exhibiting elevated viral loads, higher pro-inflammatory markers,
360 and reduced immune response efficiency due to factors like inflammation,
361 immunological aging, and changes in ACE2 receptor dynamics and cytokine profiles
362 ¹⁴. The mental state of the elderly can also impact their recovery ¹⁵.

363 Racial and ethnic minority groups have been disproportionately affected by
364 the pandemic ¹⁶. In the current cohort, 59.9% of those testing positive for COVID-19
365 identified as non-white (mixed race, Black, and other ethnicities). African Americans,
366 Hispanics, and non-Hispanic Blacks have higher infection rates than other racial and
367 ethnic groups ^{17,18}. Socioeconomic status and healthcare access significantly
368 contribute to these disparities. Lower to middle socioeconomic status is linked to
369 higher COVID-19 hospitalization rates ¹⁹. Non-white participants face increased
370 exposure risks and healthcare barriers, leading to higher chances of seroconversion
371 and hospitalization ²⁰. These findings highlight the need for equitable resource
372 distribution and targeted interventions to address COVID-19's disproportionate
373 impact on racial and ethnic minority groups.

25 Manuscript

374 Data from ten European countries indicate that working-age women have
375 higher COVID-19 diagnosis rates than men, with the trend reversing after
376 retirement. Women's higher infection rates may be due to their greater
377 representation in healthcare-related occupations ²¹. In the current study, 57.9% of
378 individuals testing positive for COVID-19 were female. The relationship between
379 gender and COVID-19 infection is complex and multifaceted. Research shows
380 gender disparities in vulnerability, severity, and outcomes of COVID-19. Despite men
381 being more susceptible to severe infection outcomes, including higher
382 hospitalization and mortality rates compared to women ²², women, due to genetic
383 and hormonal factors, exhibit a more resilient immune response. Women's
384 expression of the TLR7 gene on the X chromosome enhances their ability to produce
385 antiviral proteins and interferons in dendritic cells, protecting them against severe
386 SARS-CoV-2 infections ²². Additionally, cardiovascular conditions significantly affect
387 COVID-19 outcomes, with men exhibiting greater vulnerability compared to women
388 ²³.

389

390 *Comorbidities*

391

392 Hypertension is a primary risk factor for adverse COVID-19 outcomes,
393 associated with severe illness and increased mortality. In ²⁴, 74% of hypertensive

26 Manuscript

394 patients with moderate symptoms died, with a relative risk (RR) of 1.45 (CI 0.96-2.2).
395 ²⁵ reported a hazard ratio (HR) of 1.58 (CI 1.07-2.32) linked to hypertension, and any
396 comorbidity presence was associated with an HR of 1.79 (CI 1.16-2.77). Another
397 study found a 22% odds ratio (OR) (1.22; CI 1.12-1.33) increase in severe infection
398 among hypertensive patients. Both hypertensive (>180 mm/Hg, OR 1.93; CI 1.06-
399 3.51) and hypotensive (<120 mm/Hg, OR 1.40; CI 1.11-1.78) patients had higher
400 chances of severe COVID-19 ²⁶.

401 Hypertension may increase the risk of contracting COVID-19. For instance, in a
402 study of 140 hospitalized COVID-19 patients, 30% had hypertension ²⁷. Another study
403 with 1099 confirmed COVID-19 patients reported hypertension in 23.7% ²⁸. However,
404 these studies do not establish a causal relationship between hypertension and
405 COVID-19 infection. Conversely, other studies found no significant association
406 between hypertension and COVID-19 infection risk. A retrospective study of 1178
407 hospitalized COVID-19 patients in Wuhan found no difference in hypertension
408 prevalence (30.7%) between severe and non-severe cases or survivors and non-
409 survivors, suggesting hypertension and ACE inhibitor use may not significantly
410 increase infection risk ²⁹.

411 Diabetes is strongly associated with severe symptoms, worse outcomes, and
412 higher mortality in COVID-19 patients. Patients with diabetes often have poorer
413 prognoses and increased susceptibility to infections due to complications like

27 Manuscript

414 peripheral neuropathy and vascular insufficiency, nearly doubling the risk of death
415 ³⁰⁻³³. Recent-onset hyperglycemia and new-onset diabetes have been reported in
416 COVID-19 patients without pre-existing diabetes, suggesting a bidirectional
417 interaction ³⁴⁻³⁶. However, whether people with diabetes are inherently more prone
418 to COVID-19 infection remains unclear. Overall, diabetes is consistently associated
419 with worse outcomes and increased mortality.

420 Obesity is also linked to severe COVID-19 outcomes and mortality ³⁷. Studies
421 show obese patients are more likely to develop severe disease and require invasive
422 mechanical ventilation ^{38,39}. Obesity reduces cardiorespiratory reserves and
423 exacerbates immune dysfunction, increasing risks of hospitalization, respiratory
424 infections, airway diseases, fatty liver, hypertension, depression, type 2 diabetes,
425 cardiovascular diseases, and cancer ⁴⁰. An extensive review identified obesity as a
426 risk factor for severe COVID-19, with patients having BMI >40 kg/m² showing higher
427 odds for mechanical ventilation (2.17; CI 1.59-2.97) and mortality (1.67; CI 1.39-2.00)
428 ⁴¹.

429 In the present study, hypertension was the most common comorbidity (18.1%
430 of infected patients), followed by diabetes (4.9%) and obesity (0.3%). Only obesity
431 frequencies differed significantly between negative and positive patients (0.5% vs.
432 0.3%, χ^2 p = 0.000).

433

28 Manuscript

434 *Symptomatology*

435

436 Fever, anosmia, ageusia, cough, fatigue, shortness of breath,
437 myalgia/arthralgia, chills, nausea/vomiting, nasal congestion, diarrhea, abdominal
438 pain, hemoptysis, and conjunctival congestion are common COVID-19 symptoms
439 ^{42,43}. Gastrointestinal symptoms like nonspecific abdominal pain, watery diarrhea,
440 and ileus have also been reported ⁴⁴. Pulmonary symptoms include pneumonia,
441 ARDS, and respiratory failure, while arrhythmias and neurological symptoms are
442 extrapulmonary manifestations ⁴⁵. Long-term symptoms include lethargy, difficulty
443 concentrating, and cough. Prolonged symptoms one month post-infection are
444 associated with being female, having chronic lung disease, and hypertension ⁴⁶.

445 COVID-19 requires differential diagnosis due to nonspecific symptoms ⁴⁷. It
446 includes other respiratory diseases like influenza and pre-existing lung pathologies
447 ⁴⁸. Symptoms such as cough, fever, shortness of breath, and headache overlap with
448 other respiratory infections and flu-like illnesses ⁴⁹. Radiological features of COVID-
449 19 pneumonia, like ground-glass opacities, crazy-paving patterns, and
450 consolidations, challenge differential diagnosis ⁵⁰. A multidisciplinary approach and
451 specific diagnostic tests, such as SARS-CoV-2 antigen determination, are crucial for
452 accurate diagnosis.

29 Manuscript

453 In the present study, the most prevalent symptoms in positive patients were
454 high fever ($\geq 38.5^{\circ}\text{C}$; 15.8%, $p = 0.002$), low fever ($< 38.5^{\circ}\text{C}$; 34.9%, $p = 0.002$), loss of
455 smell (29.3%, $p = 0.000$), loss of taste (26.6%, $p = 0.000$), and myalgia (37.4%, $p < 0.04$).
456 Testing positive for COVID-19 is linked to symptoms like fever (both high and low),
457 loss of smell, loss of taste, and myalgia, as documented in the literature ⁵¹. Myalgia,
458 common in viral disorders and other inflammatory conditions, often presents in
459 patients with hypertension and fever, indicating a systemic response to infections ⁵².
460 Changes in taste and smell, distinctive of COVID-19 ⁵³, are also associated with
461 metabolic conditions like obesity, where systemic inflammation can affect sensory
462 function ⁵⁴. High fever, a marker of systemic inflammatory response, can signal
463 complications in patients with hypertension or diabetes, where inadequate control
464 of underlying conditions may predispose to complications ⁵⁵.

465

466 *Vaccination*

467

468 Table 5 highlights a significant relationship between the number of vaccine
469 doses and negative COVID-19 test outcomes ($p = 0.002$). COVID-19 vaccination status
470 (vaccinated or not vaccinated) was significantly linked to test results (negative or
471 positive) ($p = 0.014$, Pearson's χ^2 test). These findings underscore that vaccination
472 significantly reduces the risk of testing positive for COVID-19, with most positive

30 Manuscript

473 cases occurring in unvaccinated individuals, while the majority of vaccinated
474 individuals test negative.

475 Independent evidence supports this relationship. Studies have indicated a
476 higher proportion of COVID-19 positive cases among unvaccinated individuals
477 compared to those who have received at least one vaccine dose ⁵⁶. Additionally,
478 vaccination has been shown to reduce risks of hospitalization, ICU admissions, and
479 oxygen requirement ⁵⁷. Vaccination plays a pivotal role in mitigating severe COVID-19
480 cases, especially in fully vaccinated individuals. Social determinants such as age,
481 income, education, and migration history also influence COVID-19 vaccination
482 uptake, with higher rates among older adults, individuals with higher education and
483 income levels, and lower rates among those with a migration history ⁵⁸. Recent
484 clinical trials have underscored the efficacy of mRNA vaccines in preventing virus
485 infection ⁵⁹. These insights highlight the critical role of vaccination in preventing
486 COVID-19 infection and reducing disease severity.

487

488 **Final remarks**

489

490 Our data offers a comprehensive view of sociodemographic characteristics,
491 comorbidities, symptoms, and COVID-19 test outcomes among participants. Key
492 findings include:

31 Manuscript

493

494 • Participants were predominantly of mixed race, followed by Caucasian and
495 Black individuals, with females outnumbering males. The age group 21-50
496 years was most represented, while those 81 years or older were least
497 represented.

498 • Most participants did not report hypertension, diabetes, or obesity, although
499 hypertension was the most prevalent among those who did.

500 • Reported symptoms varied widely, with headache being the most common.
501 Fever above 38.5°C, loss of smell, and loss of taste were frequent among
502 those testing positive for COVID-19, but a significant proportion of positive
503 cases did not show these symptoms.

504 • Age significantly affected the likelihood of testing positive.

505 • Hypertension was more commonly associated with positive COVID-19 tests
506 among participants with comorbidities, while diabetes and obesity were less
507 prevalent among those testing positive.

508 • Fever, loss of smell, loss of taste, and headache were key indicators of
509 infection. Vaccination significantly reduced positive test rates, with a higher
510 proportion of unvaccinated participants testing positive.

511

32 Manuscript

512 In conclusion, these insights can guide targeted strategies for prevention,
513 screening, and treatment, and identify at-risk populations.

514

515 **Acknowledgements**

516

517 *Ethical approval*

518

519 The present research protocol was reviewed and approved by the Research
520 Ethics Committee of the University of Grande Rio (CEP/UNIGRANRIO) under CAAE
521 number 32362220.1.0000.5283.

522

523 *Conflicts of interest*

524

525 Authors declare having no conflicts of interest.

526

527 *Funding*

528

529 This work was supported by the National Council for Scientific and
530 Technological Development (CNPq, Brazil) [152071/2020-2], the Tess Research
531 Foundation (TRF, USA), [Early-Career Investigator Research Grant 2022/2023], the

33 Manuscript

532 Carlos Chagas Filho Research Support Foundation of the State of Rio de Janeiro
533 (FAPERJ) [Emergencial E-26/211.041/2021 and JCNE E-26/201.434/2021].

534

535 **References**

536

- 537 1. Khalil OAK, Khalil SDS. SARS-CoV-2: taxonomia, origem e constituição. Rev Med
538 (São Paulo). 2020 Dec 10;99(5):473–9.
- 539 2. Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A,
540 Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared
541 with SARS-CoV-1. N Engl J Med. 2020 Apr 16;382(16):1564–7.
- 542 3. World Health Organization. Novel Coronavirus (2019-nCoV) - SITUATION
543 REPORT 1 [Internet]. World Health Organization; 2020 [cited 2023 Sep 9] p. 5.
544 Report No.: 1. Available from:
545 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/
546 20200121-sitrep-1-2019-ncov.pdf](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf)
- 547 4. World Health Organization. COVID-19 Weekly Epidemiological Update
548 [Internet]. World Health Organization; 2023 Mar [cited 2023 Sep 9] p. 19.
549 Report No.: 134. Available from:
550 [https://apps.who.int/iris/bitstream/handle/10665/366534/nCoV-weekly-
551 sitrep16Mar23-eng.pdf?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/366534/nCoV-weekly-sitrep16Mar23-eng.pdf?sequence=1)
- 552 5. Sharaf S, Athikkavil FM, Varghese SD, Sreekumar S, Ramakrishnan R, Varghese
553 J, et al. COVID-19: global pandemic with divergent waves: an exigent public
554 health concern worldwide with special context to Indian scenario. Int J
555 Community Med Public Health. 2022 Feb 28;9(3):1547.
- 556 6. Dey SK, Rahman MdM, Siddiqi UR, Howlader A, Tushar MdA, Qazi A. Global
557 landscape of COVID-19 vaccination progress: insight from an exploratory data
558 analysis. Human Vaccines & Immunotherapeutics. 2022 Jan 31;18(1):2025009.
- 559 7. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and
560 effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and
561 COVID-19 cases, hospitalisations, and deaths following a nationwide

34 Manuscript

- 562 vaccination campaign in Israel: an observational study using national
563 surveillance data. *The Lancet*. 2021 May;397(10287):1819–29.
- 564 8. Carvalho T, Krammer F, Iwasaki A. The first 12 months of COVID-19: a timeline
565 of immunological insights. *Nat Rev Immunol*. 2021 Apr;21(4):245–56.
- 566 9. Domingues CMAS. Desafios para a realização da campanha de vacinação
567 contra a COVID-19 no Brasil. *Cad Saúde Pública*. 2021;37(1):e00344620.
- 568 10. Oliveira AGD, Silviera D. DESENVOLVIMENTO DE VACINAS CONTRA COVID-19.
569 COOPERAÇÃO OU COMPETIÇÃO INTERNACIONAL? *Infarma*. 2020 Sep
570 28;32(3):175–8.
- 571 11. Abreu IR, Alexandre MMM, Costa MCVD, Botelho JMG, Alves LCB, Lima AA.
572 Impact of the COVID-19 pandemic on vaccination coverage in children in
573 Brazil: A literature review. *RSD*. 2022 Oct 24;11(14):e213111436227.
- 574 12. IBGE. São Gonçalo (RJ) | Cidades e Estados | IBGE [Internet]. 2024 [cited 2024
575 Jan 26]. Available from: <https://www.ibge.gov.br/cidades-e-estados/rj/sao-goncalo.html>
576
- 577 13. Cleophas TJ, Zwinderman AH. *Statistics Applied to Clinical Studies* [Internet].
578 Dordrecht: Springer Netherlands; 2012 [cited 2023 Sep 9]. Available from:
579 <http://link.springer.com/10.1007/978-94-007-2863-9>
- 580 14. Cham LB, Pahus MH, Grønhøj K, Olesen R, Ngo H, Monrad I, et al. Effect of Age
581 on Innate and Adaptive Immunity in Hospitalized COVID-19 Patients. *JCM*.
582 2021 Oct 19;10(20):4798.
- 583 15. Zhang S, Yang Z, Li ZN, Chen ZL, Yue SJ, Fu RJ, et al. Are Older People Really
584 More Susceptible to SARS-CoV-2? *Aging and disease*. 2022;13(5):1336.
- 585 16. Barnes MPJ. *Relationships Between COVID-19 Infection Rates, Healthcare
586 Access, Socioeconomic Status, and Cultural Diversity* [Internet] [Master of
587 Science in Mathematics]. [Boise, ID]: Boise State University; 2022 [cited 2023
588 Oct 25]. Available from: <https://scholarworks.boisestate.edu/td/1964/>
- 589 17. Luo J, Craver A, Zakin P, Stepniak L, Moore K, King J, et al. Race may modify the
590 association between blood type and COVID-19 infection. *ejHaem*. 2022
591 Aug;3(3):903–7.

35 Manuscript

- 592 18. Robertson M, Shamsunder M, Brazier E, Mantravadi M, Rane MS,
593 Westmoreland DA, et al. Racial/ethnic disparities in exposure to COVID-19,
594 susceptibility to COVID-19 and access to health care - findings from a U.S.
595 national cohort [Internet]. *Epidemiology*; 2022 Jan [cited 2023 Oct 25].
596 Available from: <http://medrxiv.org/lookup/doi/10.1101/2022.01.11.22269101>
- 597 19. Faberman RJ, Hartley D. The Relationship between Race, Type of Work, and
598 Covid-19 Infection Rates [Internet]. Federal Reserve Bank of Chicago; 2020
599 [cited 2023 Oct 25]. Available from:
600 [https://www.chicagofed.org/~media/publications/working-papers/2020/
601 wp2020-18-pdf.pdf](https://www.chicagofed.org/~media/publications/working-papers/2020/wp2020-18-pdf.pdf)
- 602 20. Kimani ME, Sarr M, Cuffee Y, Liu C, Webster NS. Associations of Race/Ethnicity
603 and Food Insecurity With COVID-19 Infection Rates Across US Counties. *JAMA*
604 *Netw Open*. 2021 Jun 8;4(6):e2112852.
- 605 21. Sobotka T, Brzozowska Z, Muttarak R, Zeman K, Di Lego V. Age, gender and
606 COVID-19 infections [Internet]. *Public and Global Health*; 2020 May [cited 2023
607 Oct 25]. Available from:
608 <http://medrxiv.org/lookup/doi/10.1101/2020.05.24.20111765>
- 609 22. Zovi A, Ferrara F, Langella R, Cavallaro F, Vitiello A. Sex affects immune
610 response capacity against COVID-19 infection. *Reviews in Medical Virology*.
611 2023 Jul;33(4):e2450.
- 612 23. Chaturvedi R, Lui B, Aaronson JA, White RS, Samuels JD. COVID-19
613 complications in males and females: recent developments. *J Comp Eff Res*.
614 2022 Jun;11(9):689-98.
- 615 24. Oliveira MAD, Haddad A, Godomiczer A, Garcia TR, Sten C, Moisés FP, et al.
616 HYPERTENSION AND RISK FACTOR TO MORTALITY IN CORONAVIRUS DISEASE
617 (COVID-19). *Journal of Hypertension*. 2023 Jun;41(Suppl 3):e191.
- 618 25. Guan W jie, Liang W hua, Zhao Y, Liang H rui, Chen Z sheng, Li Y min, et al.
619 Comorbidity and its impact on 1590 patients with COVID-19 in China: a
620 nationwide analysis. *Eur Respir J*. 2020 May;55(5):2000547.
- 621 26. Pavey H, Kulkarni S, Wood A, Ben-Shlomo Y, Sever P, McEniery C, et al. Primary
622 hypertension, anti-hypertensive medications and the risk of severe COVID-19
623 in UK Biobank. Karnik SS, editor. *PLoS ONE*. 2022 Nov 9;17(11):e0276781.

36 Manuscript

- 624 27. Zhang J jin, Dong X, Cao Y yuan, Yuan Y dong, Yang Y bin, Yan Y qin, et al.
625 Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan,
626 China. *Allergy*. 2020 Jul;75(7):1730–41.
- 627 28. Guan W jie, Ni Z yi, Hu Y, Liang W hua, Ou C quan, He J xing, et al. Clinical
628 Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020 Apr
629 30;382(18):1708–20.
- 630 29. Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin
631 System Inhibitors With Severity or Risk of Death in Patients With Hypertension
632 Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan,
633 China. *JAMA Cardiol*. 2020 Jul 1;5(7):825–30.
- 634 30. Dahlia D, Artanti KD, Hargono A, Martini S, Nasr NMG, Li CY. Death risk among
635 COVID-19 patients with diabetes mellitus. *J Public Health Afr [Internet]*. 2022
636 Dec 7 [cited 2023 Oct 6];13(s2). Available from:
637 <https://www.publichealthinafrica.org/jphia/article/view/2399>
- 638 31. Fadhil Okab H, Khazaal Yassir H, Mohammed Majed M. Estimation of
639 Immunological and Physiological Parameters in Diabetic Patients with COVID-
640 19. *RB*. 2023 Jun 15;8(2):1–4.
- 641 32. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes
642 mellitus associated with mortality and severity of COVID-19? A meta-analysis.
643 *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2020
644 Jul;14(4):535–45.
- 645 33. Zahraa ALBasry, Abeer Abdulhadi Rashid, Shaymaa Hasan Abbas. Severity of
646 Symptoms and Mortality in Diabetic Patients with COVID- 19 Infection. *Review*.
647 *AJPS*. 2023 Mar 1;23(1):91–104.
- 648 34. Dallavalasa S, Tulimilli SV, Prakash J, Ramachandra R, Madhunapantula SV,
649 Veeranna RP. COVID-19: Diabetes Perspective—Pathophysiology and
650 Management. *Pathogens*. 2023 Jan 25;12(2):184.
- 651 35. Lima-Martínez MM, Carrera Boada C, Madera-Silva MD, Marín W, Contreras M.
652 COVID-19 y diabetes mellitus: una relación bidireccional. *Clínica e*
653 *Investigación en Arteriosclerosis*. 2021 May;33(3):151–7.
- 654 36. Wong R, Lam E, Bramante CT, Johnson SG, Reusch J, Wilkins KJ, et al. Does
655 COVID-19 Infection Increase the Risk of Diabetes? Current Evidence. *Curr Diab*
656 *Rep*. 2023 Aug;23(8):207–16.

37 Manuscript

- 657 37. Ribeiro AC, Poli P, Uehara SCDSA. Increased risk of mortality from COVID-19 in
658 people with obesity. *Rev Rene*. 2023 Jan 24;24:e81453.
- 659 38. Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, et al. Obesity and COVID-19 Severity
660 in a Designated Hospital in Shenzhen, China. *Diabetes Care*. 2020 Jul
661 1;43(7):1392–8.
- 662 39. Sattar N, McInnes IB, McMurray JJV. Obesity Is a Risk Factor for Severe COVID-
663 19 Infection: Multiple Potential Mechanisms. *Circulation*. 2020 Jul 7;142(1):4–6.
- 664 40. Al-Baka HAA, Aldujaili HH. Obesity and Covid-19 Severity. *IJFMT [Internet]*. 2021
665 May 12 [cited 2023 Oct 27]; Available from:
666 <http://medicopublication.com/index.php/ijfmt/article/view/16267>
- 667 41. Tadayon Najafabadi B, Rayner DG, Shokraee K, Shokraie K, Panahi P, Rastgou P,
668 et al. Obesity as an independent risk factor for COVID-19 severity and
669 mortality. *Cochrane Database Syst Rev*. 2023 May 24;5(5):CD015201.
- 670 42. Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J, et al. Manifestations and prognosis of
671 gastrointestinal and liver involvement in patients with COVID-19: a systematic
672 review and meta-analysis. *The Lancet Gastroenterology & Hepatology*. 2020
673 Jul;5(7):667–78.
- 674 43. Tahvildari A, Arbabi M, Farsi Y, Jamshidi P, Hasanzadeh S, Calcagno TM, et al.
675 Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized
676 Patients: A Systematic Review of Case Reports and Case Series. *Front Med*.
677 2020 May 15;7:231.
- 678 44. Yildirim AC, Alkan Ceviker S, Zeren S, Ekici MF, Yaylak F, Algin MC, et al. COVID-
679 19 and related gastrointestinal symptoms: An observational study. *Marmara
680 Medical Journal*. 2022 May 30;35(2):244–8.
- 681 45. Schmeelk S, Davis A, Li Q, Shippey C, Utah M, Myers A, et al. Monitoring
682 Symptoms of COVID-19: Review of Mobile Apps. *JMIR Mhealth Uhealth*. 2022
683 Jun 1;10(6):e36065.
- 684 46. Solehan HM, Mohamed NA, Mohd Rani MD, Ithnin M. Post-COVID-19
685 Symptoms, an Online Survey in Malaysia. *imjm [Internet]*. 2022 Oct 1 [cited
686 2023 Oct 28];21(4). Available from:
687 <https://journals.iium.edu.my/kom/index.php/imjm/article/view/2100>

38 Manuscript

- 688 47. Orlova NV, Nikiforov VV. An integrated approach to the differential diagnosis of
689 COVID-19 syndromes and symptoms. *Epidemiology and Infectious Diseases*.
690 2022 May 25;26(2):44–56.
- 691 48. Perrone F, Balbi M, Casartelli C, Buti S, Milanese G, Sverzellati N, et al.
692 Differential diagnosis of COVID-19 at the chest computed tomography scan: A
693 review with special focus on cancer patients. *World J Radiol*. 2021 Aug
694 28;13(8):243–57.
- 695 49. Alemi F, Vang J, Wojtusiak J, Guralnik E, Peterson R, Roess A, et al. Differential
696 diagnosis of COVID-19 and influenza. Sheel M, editor. *PLOS Glob Public Health*.
697 2022 Jul 21;2(7):e0000221.
- 698 50. Marginean CM, Popescu M, Vasile CM, Cioboata R, Mitrut P, Popescu IAS, et al.
699 Challenges in the Differential Diagnosis of COVID-19 Pneumonia: A Pictorial
700 Review. *Diagnostics*. 2022 Nov 16;12(11):2823.
- 701 51. Hara M, Furue T, Fukuoka M, Iwanaga K, Matsuishi E, Miike T, et al.
702 Comparison of self-reported symptoms in COVID-19 patients who had or had
703 not previously received COVID-19 mRNA vaccination. *Human Vaccines &*
704 *Immunotherapeutics*. 2023 Aug;19(2):2226575.
- 705 52. Morgan L, Hollist M, Au K, Ayari L, Betts C, Kirmani BF. Neuromuscular
706 Disorders Associated With COVID-19. *J Exp Neurosci*. 2023
707 Jan;18:263310552311762.
- 708 53. Tsukahara T, Brann DH, Datta SR. Mechanisms of SARS-CoV-2-associated
709 anosmia. *Physiological Reviews*. 2023 Oct 1;103(4):2759–66.
- 710 54. Siena C, Anita B, Sara D GD. Impact of Metabolic Syndrome on Retronasal
711 Olfaction. *Arch Metabolic Syndr* [Internet]. 2022 Dec 31 [cited 2024 Jan 29];2(2).
712 Available from: [https://www.scivisionpub.com/pdfs/impact-of-metabolic-](https://www.scivisionpub.com/pdfs/impact-of-metabolic-syndrome-on-retronasal-olfaction-2517.pdf)
713 [syndrome-on-retronasal-olfaction-2517.pdf](https://www.scivisionpub.com/pdfs/impact-of-metabolic-syndrome-on-retronasal-olfaction-2517.pdf)
- 714 55. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group
715 of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of
716 Wuhan, China: retrospective case series. *BMJ*. 2020 Feb 19;m606.
- 717 56. Andrews A, C. Mathew A, Mathew T. COVID-19 vaccination status and its effect
718 on outcome and disease severity. *Int J Community Med Public Health*. 2023 Jan
719 12;10(2):629–34.

39 Manuscript

- 720 57. Chahbi Z, Raiteb M, Mouharir M, Belatik I, Badaoui M, Kaddouri S, et al.
721 Evolution of COVID-19 According to Vaccination Status in a Moroccan Cohort.
722 SAS J Med. 2023 Jun 10;9(06):646–9.
- 723 58. Purwanti ED, Ronoatmojo S. Association Between COVID-19 Vaccination Status
724 With Severity of Confirmed COVID-19 Patients Period of January-July 2022 in
725 Indonesia. JIKM. 2023 Mar 30;14(1):13–26.
- 726 59. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety
727 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec
728 31;383(27):2603–15.

729

730 **Supplementary tables**

731

732 **Supplementary table 1.** Comorbidities present in the sample of participants
733 (patients) who were attended at the screening centers of São Gonçalo (RJ), during
734 the period from 07/28/2021 to 12/02/2021.

Variables	N = 6,953 ¹
HYPERTENSION	
No	5,652 (82%)
Yes	1,253 (18%)
Not available	48
DIABETES	
No	6,560 (95%)
Yes	339 (4.9%)
Not available	54
OBESITY	
No	6,855 (100%)
Yes	31 (0.5%)
Not available	67

¹n (%)

735